Diasome Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Diasome Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10847
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Diasome Pharmaceuticals Inc (Diasome) is a pharmaceutical company that focusses on clinical and commercial development of therapies for diabetes and obesity. The company offers products in the fields of cell receptor targeting, insulin replacement, and hepatic (liver) glucose metabolism. Its pipeline products include multiple injected and oral formulations of liver targeted insulin’s for both type 1 and type 2 diabetic patients. Diasome’s products include injectable HDV insulin, oral HDV insulin and oral HDV + novel T2DM candidates among others. The company’s technology platform is based on the use of its proprietary Hepatocyte directed vesicle, or HDV, nanotechnology to deliver a wide range of necessary hormones and drugs to the liver. It partners with other pharmaceutical companies. Diasome is headquartered in Cleveland, Ohio, the US.

Diasome Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Diasome Pharma Raises up to USD30 Million in Venture Financing 10
Diasome Pharma Raises USD4.4 Million in Venture Financing 11
Partnerships 12
Diasome Pharma Enters into Agreement with Lyfebulb 12
Diasome Pharma Enters into Agreement with Joslin Diabetes Center 13
Licensing Agreements 14
Diasome Pharma Enters into Licensing Agreement with SDG 14
Diasome Pharmaceuticals Inc – Key Competitors 15
Diasome Pharmaceuticals Inc – Key Employees 16
Diasome Pharmaceuticals Inc – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Diasome Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Diasome Pharma Raises up to USD30 Million in Venture Financing 10
Diasome Pharma Raises USD4.4 Million in Venture Financing 11
Diasome Pharma Enters into Agreement with Lyfebulb 12
Diasome Pharma Enters into Agreement with Joslin Diabetes Center 13
Diasome Pharma Enters into Licensing Agreement with SDG 14
Diasome Pharmaceuticals Inc, Key Competitors 15
Diasome Pharmaceuticals Inc, Key Employees 16

List of Figures
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Diasome Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Diasome Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TAS Energy Inc-エネルギー分野:企業M&A・提携分析
    Summary TAS Energy, Inc. (TAS), formerly Turbine Air Systems, Ltd., offers clean and modular energy solutions. The company designs, manufactures and supplies turbine inlet chilling systems for power augmentation; modular utility systems for air cooling; waste heat/geothermal systems for power genera …
  • Bonduelle Sca:企業の戦略・SWOT・財務分析
    Bonduelle Sca - Strategy, SWOT and Corporate Finance Report Summary Bonduelle Sca - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • ConceptoMed AS:医療機器:M&Aディール及び事業提携情報
    Summary ConceptoMed AS (ConceptoMed) is a medical device company that offers medtech systems. The company offers Luer-Jack, a medical syringe facilitating safer conditions for performing medical procedures. Its Luer-Jack provides superior usability advantages, preventing dislodging of the sharp need …
  • Denison Mines Corp (DNN):企業の財務・戦略的SWOT分析
    Denison Mines Corp (DNN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Hikal Ltd (HIKAL):企業の財務・戦略的SWOT分析
    Summary Hikal Ltd (Hikal) is a pharmaceutical company that provides custom manufacturing; active ingredients and intermediates. The company provides product portfolio such as antiepileptic, antihistamine, antipsychotic and antilipemic, among others. It offers services such as custom synthesis, contr …
  • Ingles Markets Inc:企業の戦略・SWOT・財務情報
    Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report Summary Ingles Markets Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GVK Biosciences Pvt Ltd-製薬・医療分野:企業M&A・提携分析
    Summary GVK Biosciences Pvt Ltd (GVK BIO) is a contract research organization that offers contract manufacturing and research services. The organization provides services such as discovery services, integrated programs, clinical development, contract manufacturing, formulations and informatics. It p …
  • AES Gener SA (AESGENER):企業の財務・戦略的SWOT分析
    AES Gener SA (AESGENER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Central Securities Corp (CET):企業の財務・戦略的SWOT分析
    Summary Central Securities Corp (Central Securities) is a financial service provider that provides investment services. The company offers investment management services and stock investment related services. It invests on convertible preferred stocks, bonds, preferred stocks, convertible bonds, war …
  • McAfee, Inc.:企業の戦略的SWOT分析
    McAfee, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • ARCA biopharma Inc (ABIO):企業の財務・戦略的SWOT分析
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Dana Petroleum Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Dana Petroleum Ltd (Dana), a wholly-owned subsidiary of Korea National Oil Corp (KNOC), is an upstream oil and gas company. It explores, develops and produces oil and gas from its assets in the Europe and the Middle East. The company has interests and operations in the UK, the Netherlands, D …
  • Barkers (Northallerton) Limited:企業の戦略的SWOT分析
    Barkers (Northallerton) Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Advanced Accelerator Applications SA (AAAP)-製薬・医療分野:企業M&A・提携分析
    Summary Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment o …
  • NV Nederlandse Spoorwegen:企業の戦略・SWOT・財務情報
    NV Nederlandse Spoorwegen - Strategy, SWOT and Corporate Finance Report Summary NV Nederlandse Spoorwegen - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • MediaCorp Pte Ltd:企業の戦略的SWOT分析
    MediaCorp Pte Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Continental Resources, Inc.:企業の戦略・SWOT・財務情報
    Continental Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Continental Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • CITGO Petroleum Corporation:企業の戦略・SWOT・財務情報
    CITGO Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary CITGO Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • AstraZeneca Plc (AZN):企業の財務・戦略的SWOT分析
    AstraZeneca Plc (AZN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Manila Electric Co (MER):電力:M&Aディール及び事業提携情報
    Summary Manila Electric Co (MERALCO) is an electric distribution utility company. It constructs, operates and maintains the electricity distribution system in the cities and municipalities of Bulacan, Metro Manila, Cavite, and Rizal and certain cities, municipalities, and barangays in the provinces …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆